Nls pharmaceutics announces company update webcast

Members of executive leadership team to discuss initiation of phase 3, pipeline updates, key financials, corporate development, and the other topics nls to webcast its event friday, june 30 at 11:00am et zurich, switzerland / accesswire / june 15, 2023 / nls pharmaceutics ltd. (nasdaq:nlsp)(nasdaq:nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced plans to showcase its global strategic r&d progress and platform, including: feedback from the sleep 2023 apss conference initiation of the phase 3 program aware for mazindol er pipeline goals for 2023/2024 key financials funding strategy update corporate development webcast information the event will be held june 30, 2023, at 11:00 am et and will include a video stream on the investors section of the company's website here.
NLSP Ratings Summary
NLSP Quant Ranking